Cohance Lifesciences Limited (BOM:543064)

Market Cap	386.24B
Revenue (ttm)	11.98B
Net Income (ttm)	2.68B
Shares Out	n/a
EPS (ttm)	10.45
PE Ratio	144.19
Forward PE	58.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,512
Average Volume	7,204
Open	1,003.15
Previous Close	1,003.85
Day's Range	981.00 - 1,007.10
52-Week Range	656.35 - 1,359.00
Beta	n/a
RSI	35.26
Earnings Date	May 28, 2025

About Cohance Lifesciences

Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research services. It also manufactures finished dosage formulations for pharmaceutical companies; and specialty chemicals, such as electronic chemicals. The company ...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,193
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.